Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00096746
Status:
COMPLETED
Last Update Posted:
2011-04-13
First Post:
2004-11-15
Brief Title:
Effect of the Atazanavir ATV 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
An Exploratory Study of the Effect of the Atazanavir ATV I50L Mutation on Subsequent Treatment Response
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will compare the response of subjects who failed a first-line ATV-containing regimen and who have the 150L-containing virus to subsequent protease inhibitor PI-containing therapy with that of a cohort who has failed a first-line reverse transcriptase inhibitor NNRTI and is subsequently receiving PI-containing therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None